This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Cosentyx
  • /
  • An Open-label, Prospective, Non-randomized, Multic...
Clinical trial

An Open-label, Prospective, Non-randomized, Multicenter Study to Evaluate Clear Skin Effect on Health Related Quality of Life Outcomes at 16 and 52 Weeks in Patients With Moderate to Severe Plaque Psoriasis Treated With Secukinumab 300 mg s.c. With or Wit

Read time: 2 mins
Last updated:1st Mar 2016
Identifier: NCT02752776
Study of effects of secukinumab 300 mg s.c. on quality of life (QoL) in psoriasis patients with or without prior exposure to systemic therapy.

 

Category Value
Date last updated at source 2016-04-22
Study type(s) Interventional
Expected enrolment 1615
Study start date 2016-03-01
Estimated primary completion date 2018-11-01

View full details